Mackenzie Financial’s Zimmer Biomet ZBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.16M Buy
101,318
+2,337
+2% +$214K 0.01% 540
2025
Q4
$8.97M Buy
98,981
+10,600
+12% +$1.01M 0.01% 528
2025
Q3
$8.71M Buy
88,381
+17,661
+25% +$1.75M 0.01% 524
2025
Q2
$6.45M Buy
70,720
+4,282
+6% +$414K 0.01% 555
2025
Q1
$7.52M Buy
66,438
+6,547
+11% +$700K 0.01% 504
2024
Q4
$6.33M Buy
59,891
+3,899
+7% +$418K 0.01% 538
2024
Q3
$6.04M Buy
55,992
+6,789
+14% +$741K 0.01% 519
2024
Q2
$5.34M Sell
49,203
-31,930
-39% -$3.76M 0.01% 534
2024
Q1
$10.7M Sell
81,133
-36,457
-31% -$4.55M 0.02% 428
2023
Q4
$14.3M Buy
117,590
+1,371
+1% +$153K 0.02% 386
2023
Q3
$12.8M Buy
116,219
+1,839
+2% +$234K 0.02% 386
2023
Q2
$16.3M Buy
114,380
+89,855
+366% +$12.2M 0.02% 368
2023
Q1
$3.17M Buy
24,525
+252
+1% +$31.6K ﹤0.01% 641
2022
Q4
$3.09M Buy
24,273
+2,236
+10% +$259K 0.01% 590
2022
Q3
$2.3M Sell
22,037
-143,459
-87% -$15.7M ﹤0.01% 663
2022
Q2
$17.4M Sell
165,496
-4,513
-3% -$535K 0.03% 344
2022
Q1
$21.7M Sell
170,009
-3,810
-2% -$459K 0.03% 341
2021
Q4
$21.4M Sell
173,819
-6,673
-4% -$873K 0.03% 347
2021
Q3
$25.6M Buy
180,492
+9,884
+6% +$1.45M 0.04% 308
2021
Q2
$26.6M Buy
170,608
+10,764
+7% +$1.74M 0.04% 298
2021
Q1
$24.8M Sell
159,844
-22,837
-13% -$3.54M 0.04% 287
2020
Q4
$27.3M Sell
182,681
-24,069
-12% -$3.4M 0.06% 231
2020
Q3
$27.3M Sell
206,750
-2,937
-1% -$384K 0.07% 209
2020
Q2
$24.3M Sell
209,687
-23,661
-10% -$2.73M 0.07% 214
2020
Q1
$22.9M Sell
233,348
-137,462
-37% -$18M 0.07% 207
2019
Q4
$53.9M Sell
370,810
-23,135
-6% -$3.19M 0.13% 165
2019
Q3
$52.5M Sell
393,945
-164,075
-29% -$21.2M 0.14% 162
2019
Q2
$63.8M Buy
558,020
+21,370
+4% +$2.5M 0.16% 146
2019
Q1
$66.5M Buy
536,650
+217,039
+68% +$24.7M 0.16% 147
2018
Q4
$32.2M Buy
319,611
+70,412
+28% +$7.92M 0.08% 201
2018
Q3
$31.8M Buy
249,199
+14,913
+6% +$1.77M 0.08% 198
2018
Q2
$25.3M Buy
234,286
+44,381
+23% +$4.83M 0.06% 212
2018
Q1
$20.1M Buy
189,905
+75,750
+66% +$8.8M 0.05% 242
2017
Q4
$13.4M Buy
114,155
+97,615
+590% +$11M 0.03% 308
2017
Q3
$1.88M Buy
+16,540
New +$1.91M 0.01% 394
2017
Q2
Sell
-4,449
Closed -$527K 679
2017
Q1
$527K Sell
4,449
-5,762
-56% -$653K ﹤0.01% 520
2016
Q4
$1.02M Buy
10,211
+3,687
+57% +$395K 0.01% 440
2016
Q3
$824K Sell
6,524
-11,430
-64% -$1.41M 0.01% 438
2016
Q2
$2.1M Buy
17,954
+33
+0.2% +$3.73K 0.01% 428
2016
Q1
$1.85M Buy
17,921
+6,212
+53% +$601K 0.02% 366
2015
Q4
$1.17M Hold
11,709
0.01% 513
2015
Q3
$1.07M Sell
11,709
-6,895
-37% -$691K 0.01% 525
2015
Q2
$1.97M Sell
18,604
-4,266
-19% -$472K 0.01% 431
2015
Q1
$2.61M Sell
22,870
-14,664
-39% -$1.67M 0.01% 387
2014
Q4
$4.13M Sell
37,534
-6,341
-14% -$668K 0.02% 338
2014
Q3
$4.28M Buy
43,875
+19,739
+82% +$1.94M 0.02% 327
2014
Q2
$2.43M Sell
24,136
-515
-2% -$50.2K 0.01% 394
2014
Q1
$2.26M Buy
24,651
+430
+2% +$39.6K 0.01% 384
2013
Q4
$2.19M Buy
24,221
+3,609
+18% +$312K 0.01% 378
2013
Q3
$1.64M Sell
20,612
-3,384
-14% -$266K 0.01% 401
2013
Q2
$1.75M Buy
+23,996
New +$1.79M 0.01% 410

Other funds holding ZBH

Mackenzie Financial's ZBH Position: Q1 2026 in Review

Mackenzie Financial increased its Zimmer Biomet (ZBH) stake by 2.4% in Q1 2026, buying an estimated $214K and bringing the position to 101,318 shares worth $9.16M. The position accounts for 0.01% of the portfolio, ranked #540.

Mackenzie Financial first reported a position in ZBH in Q2 2013 and has held it in 51 quarters since. The position peaked at $66.5M in Q1 2019. 912 funds tracked by Wall St. Rank hold ZBH as of Q1 2026.

  • Mackenzie Financial held 101,318 shares of Zimmer Biomet worth $9.16M as of Q1 2026.
  • Mackenzie Financial bought 2,337 Zimmer Biomet shares in Q1 2026, an estimated $214K.
  • Zimmer Biomet made up 0.01% of Mackenzie Financial's portfolio in Q1 2026, its #540 holding.
  • Mackenzie Financial first reported a position in Zimmer Biomet in Q2 2013 and has held it in 51 quarters since.
  • Mackenzie Financial's Zimmer Biomet position peaked at $66.5M in Q1 2019.
  • 912 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.